Project Grant R00HL166763
Award Date
5/20/25
Completion Date
4/30/28
Dollars Obligated
$245K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Binghamton, NY 13902, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 2-year, $131,485 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc. to study the role of proline metabolism in pulmonary arterial hypertension (PAH). The research aims to understand how inflammation impairs the regulation of proline in pulmonary artery endothelial cells, potentially leading to increased cell proliferation, collagen synthesis, and vascular remodeling in early-stage...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research focused on understanding the role of the RNA-binding protein ZFP36 in pulmonary arterial hypertension (PAH). The $1,535,625 award, effective July 20, 2024 through May 31, 2028, will enable researchers at the University of California, Los Angeles (UCLA) to investigate how ZFP36 regulates gene expression and impacts...
This federal Project Grant award in the amount of $692,768 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to define endothelial cell dysfunction and anoikis resistance in patients with pulmonary arterial hypertension (PAH). The research aims to leverage a "cell biopsy" method to characterize endothelial cell phenotypes and identify key mediators of anoikis resistance...
This federal Project Grant award of $596,809 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to explore the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The project aims to define how MitoNEET regulates pulmonary artery smooth muscle cell (PASMC) mitochondrial function and proliferation in vitro, examine MitoNEET expression and function during PH pathogenesis in vivo...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will fund research to investigate the role of alternative polyadenylation (APA) in right ventricular (RV) fibrosis associated with pulmonary hypertension (PH). The $760,708 award, with a project period from September 25, 2024 to September 24, 2025, will be used by the awardee, The Methodist Hospital Research Institute (HMRI), to:...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $245,626 to The Johns Hopkins University to conduct comprehensive lipidomic research on pulmonary vascular disease. The goal is to validate lipidomic signatures detected in the university's preliminary research across multiple external cohorts, investigate lipid gradients in the pulmonary vasculature, and explore relationships...
The Icahn School of Medicine at Mount Sinai received a $814,462 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to elucidate the role of the epigenetic regulator SIN3A in regulating the BMPR2 gene and pulmonary endothelial cell dysfunction in pulmonary arterial hypertension (PAH). The key objectives are to define the epigenetic mechanisms by which SIN3A regulates...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $522,794 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois to investigate the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The grant aims to elucidate the molecular mechanisms by which HV1 regulates the progression of pulmonary hypertension and explore the potential of HV1 blockers as a treatment approach. The project will utilize transgenic...
The federal Project Grant award K08HL173620, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research grant program (CFDA 93.837), supports research to examine the role of mTOR hyperactivation in pulmonary vascular remodeling and its contribution to the development and progression of pulmonary hypertension (PH). The $164,700 award, with a project period from August 15, 2024 to July 31, 2029, will leverage novel mouse models and primary lung...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $498,000.00 to National Jewish Health in Denver, Colorado to conduct research on the role of RNA editing in pulmonary hypertension. The primary objective is to investigate how the enzyme ADAR1, which regulates RNA editing, controls the survival and immune response of pulmonary artery endothelial cells and impacts the...